Showing 4,181 - 4,200 results of 4,325 for search '(( significantly mean decrease ) OR ( significantly ((better decrease) OR (greatest decrease)) ))', query time: 0.48s Refine Results
  1. 4181

    Table 2_Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment.xlsx by Xinyi Hong (8181177)

    Published 2025
    “…Various statistical methods were used, including the Wilcoxon test, multifactorial logistic regression, ROC survival curve, and Spearman’s correlation analysis.</p>Results<p>The mean serum levels of IL-17, IL-18, IL-22, IL-25, and EOS percentage in BP patients were higher than those in healthy controls (all p < 0.001), and all of these levels decreased after treatment (all p < 0.001). …”
  2. 4182

    Table 1_Effect of pain-relief nursing on activities of daily living in patients following hip arthroplasty: a systematic review and meta-analysis.docx by Jun Xie (53987)

    Published 2025
    “…Background<p>Discomfort and reduced physical function can often be significant after hip arthroplasty procedures, especially in older adults. …”
  3. 4183

    Table_1_Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients.DOC by Na Du (294594)

    Published 2024
    “…</p>Results<p>A total of 28 patients were diagnosed with PPP, including 10 males and 18 females, and 8 patients (3 males and 5 females) were diagnosed with SAPHO syndrome. The mean age was (36.3 ± 10.5) years. After 12 weeks of treatment, PPPASI scores decreased from baseline (13.86 ± 2.76) to (5.56 ± 1.08), with a statistically significant difference (p < 0.05). …”
  4. 4184

    Additional file 11 of Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma by Benjamin Lin (120565)

    Published 2025
    “…Genes were categorized as upregulated “up” or downregulated “down” by K-means clustering. Of these categorized genes, 980 and 844 are significantly (DESeq2 FDR < 0.05 and LFC > 1) increased and decreased after treatment with either drug (C). …”
  5. 4185

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  6. 4186

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  7. 4187

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  8. 4188

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  9. 4189

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  10. 4190

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  11. 4191

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  12. 4192

    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  13. 4193

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  14. 4194

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  15. 4195

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  16. 4196

    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  17. 4197

    Algorithms for designing continuous curricula A: Decision tree showing the continuous version of ADP which includes actions that “grow” and “shrink” the increments between continuo... by William L. Tong (22238845)

    Published 2025
    “…<p>See the text for more details of the task in the continuous setting. B: ADP significantly outperforms INC when the task is difficult (low <i>ε</i>). …”
  18. 4198

    Data Sheet 1_Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.docx by Peiyang Cao (10808613)

    Published 2025
    “…Notably, strong ADE signals were detected for decreased urine osmolality [n = 5, ROR 149.74, PRR 149.7, IC (Information Component) 7.13, EBGM (Empirical Bayes Geometric Mean) 139.79], osmotic demyelination syndrome (n = 38, ROR 128.47, PRR 128.25, IC 6.92, EBGM 120.91), and pulmonary-related tumors such as bronchial metastatic carcinoma, bronchial carcinoma, metastatic small cell lung carcinoma, and small cell lung carcinoma. …”
  19. 4199

    Data Sheet 1_Spatial–temporal evolution and associated factors of older adult care institutions in Shanghai.xlsx by Xingxing Yin (7919447)

    Published 2025
    “…The distribution of older adult care institutions and the aging population shows a positive trend, with the matching degree constantly increasing. The mean deviation index (M) decreased from 0.015 in 2005 to 0.011 in 2020. …”
  20. 4200

    Table 1_Effects of singing on vascular health in older adults with coronary artery disease: a randomized, crossover trial.docx by Mehri Bagherimohamadipour (21189317)

    Published 2025
    “…</p>Results<p>Sixty-five subjects (mean age 67.7 ± 0.8 years, 40% female) completed the study. …”